Literature DB >> 35035690

Bile acid metabolism and liver fibrosis following treatment with bifid triple viable capsules in nonalcoholic fatty liver disease.

Yuqing Zhou1, Wen Lu1, Guorong Yang1, Yifeng Chen1, Jiwei Cao1, Chunli Zhou1.   

Abstract

PURPOSE: This study investigated liver enzymes, bile acid metabolism, and liver fibrosis in nonalcoholic fatty liver disease (NAFLD) to evaluate the therapeutic effects of microecological preparations on fatty liver.
METHODS: Liver enzymes, liver fibrosis, and bile acids were assessed in 40 healthy volunteers and 124 NAFLD patients. All patients were retested for liver enzymes, bile acids, and liver fibrosis after two months of bifid triple viable capsule therapy.
Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05). Primary/secondary bile acids increased in patients compared to healthy controls; free/conjugated bile acids decreased (P<0.05). (2) We detected a positive correlation between total bile acid, cholic acid, chenodeoxycholic acid, deoxycholic acid, ursodeoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, taurolithocholic acid, tauroursodeoxycholic acid, and FibroScan liver stiffness. (3) Following treatment, liver enzymes decreased. Bile acids were impacted by decreasing primary/secondary bile acids and increasing free/conjugated bile acids. Improvements were observed in the fibrosis of mild fatty liver. No effects were observed for moderate and severe fatty liver.
CONCLUSIONS: Liver enzymes, bile acids, and liver fibrosis were correlated with the severity of NAFLD. There were positive correlations between bile acids and liver fibrosis. Bifid triple viable capsules could decrease liver enzymes and impact bile acid metabolism but failed to effectively improve liver fibrosis. AJTR
Copyright © 2021.

Entities:  

Keywords:  Nonalcoholic fatty liver disease; bifid triple viable capsules; bile acids; liver fibrosis

Year:  2021        PMID: 35035690      PMCID: PMC8748085     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  46 in total

1.  Steatohepatitis: a tale of two "hits"?

Authors:  C P Day; O F James
Journal:  Gastroenterology       Date:  1998-04       Impact factor: 22.682

2.  [Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update].

Authors: 
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2019-03-20

3.  Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis.

Authors:  Guoxiang Xie; Xiaoning Wang; Fengjie Huang; Aihua Zhao; Wenlian Chen; Jingyu Yan; Yunjing Zhang; Sha Lei; Kun Ge; Xiaojiao Zheng; Jiajian Liu; Mingming Su; Ping Liu; Wei Jia
Journal:  Int J Cancer       Date:  2016-06-17       Impact factor: 7.396

Review 4.  Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.

Authors:  Vincent Wai-Sun Wong; Wah-Kheong Chan; Shiv Chitturi; Yogesh Chawla; Yock Young Dan; Ajay Duseja; Jiangao Fan; Khean-Lee Goh; Masahide Hamaguchi; Etsuko Hashimoto; Seung Up Kim; Laurentius Adrianto Lesmana; Yu-Cheng Lin; Chun-Jen Liu; Yen-Hsuan Ni; Jose Sollano; Simon Kin-Hung Wong; Grace Lai-Hung Wong; Henry Lik-Yuen Chan; Geoff Farrell
Journal:  J Gastroenterol Hepatol       Date:  2018-01       Impact factor: 4.029

Review 5.  Role of Bile Acids in Metabolic Control.

Authors:  Antonio Molinaro; Annika Wahlström; Hanns-Ulrich Marschall
Journal:  Trends Endocrinol Metab       Date:  2017-11-28       Impact factor: 12.015

Review 6.  Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases.

Authors:  Harmeet Malhi; Michael Camilleri
Journal:  Curr Opin Pharmacol       Date:  2017-11-05       Impact factor: 5.547

Review 7.  Fibrosis and the intestinal microbiome; a focus on chronic liver disease.

Authors:  Naiara Beraza
Journal:  Curr Opin Pharmacol       Date:  2019-12       Impact factor: 5.547

8.  Community-Metabolome Correlations of Gut Microbiota from Child-Turcotte-Pugh of A and B Patients.

Authors:  Xiao Wei; Shan Jiang; Xiangna Zhao; Huan Li; Weishi Lin; Boxing Li; Jing Lu; Yansong Sun; Jing Yuan
Journal:  Front Microbiol       Date:  2016-11-16       Impact factor: 5.640

9.  The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.

Authors:  Dan-Ying Zhang; Lin Zhu; Hai-Ning Liu; Yu-Jen Tseng; Shu-Qiang Weng; Tao-Tao Liu; Ling Dong; Xi-Zhong Shen
Journal:  Drug Des Devel Ther       Date:  2019-07-05       Impact factor: 4.162

Review 10.  Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics.

Authors:  Xuyun He; Guang Ji; Wei Jia; Houkai Li
Journal:  Int J Mol Sci       Date:  2016-03-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.